IP Library › Granted Patent US 12679841
Granted Patent B2
US 12679841 · App. 17/541,362 · Granted Jul 14, 2026

Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors

Inventors: Peter Hewitt (Craigavon, GB); Frank Burkamp (Craigavon, GB); Andrew Wilkinson (Craigavon, GB); Hugues Miel (Craigavon, GB); Colin O'Dowd (Craigavon, GB)
C07D487/04A61K31/519A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679841
App. No.
17/541,362
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer.

Claims (20)

1 . A method of treating cancer in a human or animal patient comprising administering to the patient in need thereof an effective amount of a compound having the formula (I):

or a pharmaceutically acceptable salt or N-oxide derivative thereof;

wherein the cancer is selected from the group consisting of liver cancers, brain cancers, breast cancers, lung cancers, cervical cancers, and colon cancers.

2 . A method of treating cancer in a human or animal patient comprising administering to the patient in need thereof an effective amount of a pharmaceutical composition comprising a compound having the formula (I):

or a pharmaceutically acceptable salt or N-oxide derivative thereof, and at least one pharmaceutically acceptable excipient;

wherein the cancer is selected from the group consisting of liver cancers, brain cancers, breast cancers, lung cancers, cervical cancers, and colon cancers.

3 . The method of claim 2 comprising one or more further pharmaceutically active agents.

4 . The method of claim 1 , comprising administering to the patient in need thereof one or more further pharmaceutically active agents.

5 . The method of claim 1 , wherein the cancer is cervical cancer.

6 . The method of claim 1 , wherein the cancer is colon cancer.

7 . The method of claim 2 , wherein the cancer is cervical cancer.

8 . The method of claim 2 , wherein the cancer is colon cancer.

9 . The method of claim 1 , wherein the cancer is brain cancer.

10 . The method of claim 1 , wherein the cancer is breast cancer.

11 . The method of claim 1 , wherein the cancer is lung cancer.

12 . The method of claim 11 , wherein the lung cancer is non-small cell lung cancer.

13 . The method of claim 2 , wherein the cancer is brain cancer.

14 . The method of claim 2 , wherein the cancer is breast cancer.

15 . The method of claim 2 , wherein the cancer is lung cancer.

16 . The method of claim 2 , wherein the lung cancer is non-small cell lung cancer.